Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Space limited. Register now. Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental Medicare has chosen 15 prescription medications for price negotiations this year, building ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Update on January 24, 2025: Added the Round Weekly Pill Organizer, Chronically Chic Rose Medallion Pill Organizer Box, and Pill Joy Pill Case; updated prices and checked stock for all products.

Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Prices negotiated in this second round of talks are slated to take effect in 2027. The drugs announced Friday by the Biden administration are: Under the program's timeline, drugmakers have until Feb.